Agent86
Your earlier post stated a tie-up with DNDN would make perfect sense. Perhaps for DNDN, but not for PRR shareholders.
You made reference numerous times to "Competitors". PRR and DNDN are not competitors. Sure they are both companies whose primary product technology is in the field of immunotherapy for cancer treatment, but they are primarily targeting different cancers (albeit with some potential overlap, way downstream).
The two companies can happily co-exist. I'm not saying a takeover wont happen, just that it would be in the best interests of shareholders for the company to get well down the track before it does. At least to FDA approval but preferably into commercialisation.
- Forums
- ASX - By Stock
- IMM
- dendreon ranked highest in sales growth
dendreon ranked highest in sales growth, page-16
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
39.0¢ |
Change
-0.010(2.50%) |
Mkt cap ! $566.5M |
Open | High | Low | Value | Volume |
39.0¢ | 39.5¢ | 38.5¢ | $997.5K | 2.559M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 85852 | 38.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.0¢ | 75389 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 82255 | 0.385 |
9 | 274350 | 0.380 |
3 | 35464 | 0.375 |
5 | 94020 | 0.370 |
2 | 11078 | 0.365 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 75389 | 4 |
0.395 | 44264 | 2 |
0.400 | 176281 | 6 |
0.405 | 187434 | 3 |
0.410 | 296117 | 10 |
Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |